Guardant Health, Inc. (GH) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A section highlight strong revenue growth, improved guidance, and strategic partnerships, which are positive indicators for stock price movement. Raised revenue guidance, oncology revenue growth, and Shield's commercial expansion are significant positives. The Q&A section reveals optimism about product differentiation and regulatory strategies, although some management responses were vague. The market cap suggests moderate volatility, leading to a positive stock price movement prediction of 2% to 8% over the next two weeks.
Key Financial Performance
Revenue (Q4 2025) $281 million, representing 39% year-over-year growth. This growth reflects broad-based growth across oncology, screening, and biopharma and data businesses.
Revenue (Full Year 2025) $982 million, representing 33% year-over-year growth. This growth was driven by strong performance across all business segments.
Oncology Revenue (Q4 2025) $190 million, a 30% increase year-over-year. Growth was driven by a 38% increase in oncology test volumes to approximately 79,000 tests.
Oncology Revenue (Full Year 2025) $683.6 million, a 26% increase year-over-year. Growth was supported by a 34% increase in oncology test volumes to 276,000 tests.
Biopharma and Data Revenue (2025) $210 million, an 18% increase year-over-year. Growth was driven by strong performance in companion diagnostics and strategic partnerships.
Screening Revenue (Q4 2025) $35 million, driven by approximately 38,000 Shield tests. This was a significant increase from 24,000 tests in Q3 2025.
Screening Revenue (Full Year 2025) $79.7 million, generated from approximately 87,000 Shield tests. This was the first full calendar year since the launch of Shield.
Non-GAAP Gross Margin (Q4 2025) 66%, an improvement from 63% in the prior year. This improvement was driven by cost reductions in Reveal and Shield tests.
Non-GAAP Gross Margin (Full Year 2025) 66%, up from 62% in 2024. Improvement was primarily due to reductions in Reveal cost per test and improved Shield gross margins.
Adjusted EBITDA Loss (Q4 2025) $64.9 million, an improvement from $78.4 million in the prior year quarter. This reflects better financial performance and cost management.
Adjusted EBITDA Loss (Full Year 2025) $220.9 million, an improvement from $257.5 million in 2024. This was driven by revenue growth and operational efficiencies.
Free Cash Flow Burn (2025) $233 million, an improvement of $42 million year-over-year. The core business generated positive free cash flow in Q3 and Q4 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Guardant360 Liquid: Introduced groundbreaking applications and expanded its clinical utility with 15 smart applications.
Guardant360 Tissue: Upgraded onto the Smart Platform, gaining traction and driving deeper clinical adoption.
Reveal: Expanded for therapy monitoring and received Medicare coverage for CRC surveillance.
Shield: Expanded to include multi-cancer detection results and achieved significant volume and revenue growth.
Global Access: Launched Guardant360 CDx technology in Italy, expanding access to oncologists.
Strategic Collaborations: Collaborated with Quest Diagnostics and PathGroup to broaden Shield's reach in the U.S.
Revenue Growth: Achieved $281 million in Q4 revenue, a 39% year-over-year growth, and $982 million for the full year, a 33% increase.
Gross Margin Improvement: Non-GAAP gross margin improved to 66% in Q4, driven by cost reductions and operational efficiencies.
Cash Flow: Improved free cash flow burn to $233 million for 2025, with the core business generating positive free cash flow in Q3 and Q4.
MetaSight Acquisition: Acquired MetaSight Diagnostics to enhance CRC screening and multi-cancer detection capabilities.
AI Integration: Applied Infinity AI to develop smart applications, accelerating therapeutic discovery and biomarker development.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Reimbursement Challenges: The company faces uncertainties in obtaining Medicare reimbursement for new applications of its products, such as Reveal for breast cancer surveillance and therapy response monitoring. These challenges could delay revenue growth and adoption.
Competitive Pressures: The market for oncology and screening diagnostics is highly competitive, with other companies potentially offering similar or superior technologies. This could impact Guardant Health's market share and pricing power.
Supply Chain and Operational Risks: Scaling Shield's commercial infrastructure, including collaborations with Quest Diagnostics and PathGroup, may face logistical and operational challenges that could disrupt service delivery or increase costs.
Economic and Market Conditions: Economic uncertainties or changes in healthcare spending could impact the adoption of Guardant Health's products, particularly in markets outside the U.S.
Strategic Execution Risks: The company's aggressive R&D investments and commercial expansion plans, including the acquisition of MetaSight Diagnostics, carry risks of integration challenges and potential delays in achieving expected outcomes.
Data Privacy and Security Risks: The expansion of data repositories and partnerships involving patient data increases the risk of data breaches or non-compliance with data protection regulations, which could harm the company's reputation and financial standing.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Projections: For 2026, the company expects revenue to be in the range of $1.25 billion to $1.28 billion, representing growth of 27% to 30%. This includes oncology revenue growth of 25% to 27% and screening revenue growth to $162 million to $174 million.
Oncology Business Growth: Oncology revenue is expected to grow by 25% to 27% in 2026, supported by volume growth of approximately 30%. Key drivers include adoption of Smart apps, continued growth of Guardant360 tissue, and Reveal remaining the fastest-growing oncology product.
Screening Business Expansion: Screening revenue is projected to grow significantly to $162 million to $174 million in 2026, driven by 210,000 to 225,000 Shield tests. Sequential increases in Shield volumes are expected every quarter, with greater increases in the latter half of the year.
Biopharma and Data Business: Biopharma and data revenue is forecasted to grow at low double-digit rates in 2026, supported by ongoing collaborations and new program starts.
Gross Margin Improvements: Non-GAAP gross margin is expected to be in the range of 64% to 65% in 2026, reflecting operational improvements, volume growth, and product mix optimization.
Free Cash Flow: The company expects free cash flow burn of $185 million to $195 million in 2026, an improvement from 2025. Excluding screening, the core business is expected to be free cash flow positive for the full year.
Product Launches and Strategic Initiatives: Several new products are expected to launch in 2026, including Guardant360 Liquid CDx, ESR1 monitoring test, and Reveal Ultra. Additional apps driven by the Smart Platform and advanced reimbursement for Reveal are also anticipated.
Screening Collaborations: The company plans to drive commercial expansion with Quest Diagnostics and PathGroup collaborations, as well as expand self-pay Shield outside the U.S.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Could you elaborate further on how you're framing the opportunity for Reveal therapeutic monitoring, both for Reveal volumes and Guardant360 volumes?
A:Helmy Eltoukhy explained that Reveal for therapy monitoring is an important opportunity to synergize with Guardant360. Patients tested with Guardant360 for therapy selection can be monitored with Reveal, which bridges to the next Guardant360 test as patients progress. Reimbursement wins for IO and chemo monitoring could drive growth in oncology over the next few years.
Q:How should we think about the growth of oncology products like G360 and Reveal throughout the year?
A:Helmy Eltoukhy and Michael Bell expressed optimism for 2026, projecting at least 20% growth in Guardant360 volumes and strong growth for Reveal, which remains the fastest-growing product. They also expect acceleration in Guardant360 tissue volumes, supported by FDA approval and smart upgrades.
Q:What are your thoughts on Shield-specific burn and the pacing of rep hiring throughout 2026?
A:Michael Bell stated that the screening burn for 2026 is expected to remain at $220 million, similar to 2025. Investments will focus on building commercial infrastructure, with 2027 being a year of inflection. AmirAli Talasaz added that incremental gross profit will be reinvested into expanding the commercial organization, particularly in sales and marketing.
Q:What is your latest thinking on ADLT pricing and the oncology guide for 2026?
A:Helmy Eltoukhy mentioned that FDA submission for ADLT pricing is on track, with potential pricing changes for Guardant360 in 2027. Michael Bell noted that the 2026 oncology guide includes 30% volume growth across the portfolio, with strong traction for Guardant360, Reveal, and tissue products.
Q:What is the thought process behind Shield ASPs being down relative to 2025, and what are you baking in for international contributions?
A:Michael Bell explained that Shield ASPs are impacted by a mix of Medicare and non-Medicare demand, with the ADLT rate of $14.95 maintained for 2026 and 2027. International contributions, such as from Abu Dhabi, are expected to remain small, with most volume growth coming from the U.S.
Q:Can you talk about Reveal Ultra and its differentiation in the tumor-informed competitive landscape?
A:Helmy Eltoukhy stated that Reveal Ultra is on track for launch this year, with best-in-class clinical sensitivity and unique features that differentiate it from other tumor-informed offerings. More details will be shared later this year.
Q:What is the importance of the recent MCED legislation for Shield, and what steps are necessary for Guardant to take advantage of it?
A:AmirAli Talasaz noted that the MCED legislation is encouraging for the field but not a meaningful driver for Shield in the near term. Midterm opportunities may arise for triannual testing, but current business plans do not rely on this legislation.
Q:What has been the opt-in rate for MCED Shield, and could significant data lead to FDA submission for RSE approval?
A:AmirAli Talasaz reported good adoption rates for MCED Shield, with increasing provider and patient participation. The company aims to generate broad clinical data on MCED testing in the U.S. population, potentially leading to FDA submission in the future.
Q:What are the puts and takes of the Shield guide, and how should we think about Quest and PathGroup contributions?
A:AmirAli Talasaz explained that the Shield guide is back-half weighted, with minor contributions expected from Quest and PathGroup. The company is optimistic about ACS guidelines but has not included them in the guide. Quest and PathGroup contributions will be monitored and may lead to guidance adjustments.
Q:How are you thinking about Shield spending in 2026, including direct-to-consumer (DTC) campaigns and Quest sales force incentives?
A:AmirAli Talasaz mentioned that DTC campaigns will expand in 2026, with active campaigns being finalized. Quest salespeople are incentivized to promote Shield, and the test is seen as a differentiated brand in their portfolio.
Q:What is the path to non-cancer launch for MetaSight, and how does it integrate with your NGS platform?
A:AmirAli Talasaz expressed excitement about the MetaSight acquisition, which brings complementary technologies to the Smart Platform. Details on non-cancer launch and integration will be shared as progress is made.
Q:What does the Shield guide imply for Q1, and what could ACS guidelines mean for back-half volumes?
A:AmirAli Talasaz noted Q1 seasonality in PCP offices but expects more patients to be screened in Q1 than in any previous quarter post-launch. ACS guidelines could drive growth in younger patient populations and states with mandates, but timing remains uncertain.
Q:How do recent developments in MCED trials and FDA flexibility influence your regulatory strategy for Shield MCED?
A:AmirAli Talasaz emphasized the importance of early-stage detection performance and broad clinical evidence generation for Shield MCED. The company is optimistic about its approach to establishing utility and regulatory approval.
Q:Where is Shield demand coming from, and how much is from care gap closure versus other screening methods?
A:AmirAli Talasaz stated that Shield demand is primarily from unscreened patients, with 90% of screened patients not having been screened in the last five years. Care gap programs are not yet a growth driver, pending HEDIS qualification.
Q:What are the planned oncology investments and the timeline for NovaSeq X transition?
A:Helmy Eltoukhy and Michael Bell highlighted ongoing oncology investments based on ROI and volume growth opportunities. The NovaSeq X transition for Guardant360 is expected to complete by mid-2026, potentially improving gross margins by 200 basis points.
Q:What is the appetite for concurrent tissue and blood testing with FDA approval, and what are the reimbursement challenges?
A:Helmy Eltoukhy noted that FDA approval would enable concurrent testing, aligning with guidelines for lung and breast cancer. This could drive tissue business growth, but reimbursement challenges need to be addressed to ensure clinical utility.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the exact headcount for field force expansion, the opt-in rate for MCED Shield, and the exact contributions from Quest and PathGroup. Additionally, they used vague language regarding the 'special sauce' of Reveal Ultra and the impact of the MetaSight acquisition, leaving some questions unanswered.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CDK
CDx
Diagnostics
Gap
Italy
PathGroup
Reveal therapy
Smart Platform
Stage colon
TRICARE
barrier
biopharma partner
blood screening
cancer therapy
chemo
class
collaboration Quest
colonoscopy
companion diagnostics
detection result
finding cancer
franchise
health system
initiative
integration
life
office visit
oncology Slide
package
portfolio oncology
reach
recommendation
repository
response
role
scale
selection monitoring
set
therapy monitoring
GH Transcript
Guardant Health, Inc. (GH) Q4 2025 Earnings Call Transcript
Positive2-19
The earnings call summary and Q&A section highlight strong revenue growth, improved guidance, and strategic partnerships, which are positive indicators for stock price movement. Raised revenue guidance, oncology revenue growth, and Shield's commercial expansion are significant positives. The Q&A section reveals optimism about product differentiation and regulatory strategies, although some management responses were vague. The market cap suggests moderate volatility, leading to a positive stock price movement prediction of 2% to 8% over the next two weeks.
Guardant Health, Inc. (GH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
Guardant Health, Inc. (GH) Q3 2025 Earnings Call Transcript
Positive10-30
The earnings call summary and Q&A indicate strong revenue growth and optimistic guidance, particularly in oncology and Shield revenues. Despite some uncertainties in FDA timelines and 2026 growth, the positive reception of MCD and Guardant360's growth drivers, along with raised revenue guidance and improved margins, suggest a positive outlook. The market cap indicates a moderate reaction, leading to a 'Positive' sentiment prediction for the stock price over the next two weeks.
Guardant Health, Inc. (GH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Neutral9-8
GH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
